9435 patients receiving oral lisinopril. These observations are supported by preliminary data from ISIS-4, which has been reported,3 but not yet published, but contrast with the absence of any mortality benefit in patients treated with intravenous and oral enalapril in the 6090 patients in the CONSENSUS-11 study.
So, should all patients with myocardial infarction receive an ACE inhibitor immediately, or should such therapy be initiated later in selected patients? To resolve this question several issues have to be addressed, including the pathophysiology of ACE inhibition during and after myocardial infarction and the differences between the trials. In any event, treatment with an ACEinhibitor, once started in patients with heart failure or left ventricular dysfunction, should be continued indefinitely since long-term beneficial effects from such therapy have been shown in several large trials Survival after myocardial infarction is determined predominantly by residual left ventricular function,' which is the result of three distinct but overlapping pathophysiological processes: (a) the initial loss of myocytes (infarct size); (b) subsequent stretching and thinning of the infarcted segment during the first few days (infarct expansion), and (c) further remodelling of both infarcted and non-infarcted myocardium over several months.
Attenuation of the ischaemic insult by captopril was observed in a pig model of coronary occlusion and reperfusion.9 By comparison with saline, release of creatine kinase, inosine, and noradrenaline was reduced by the 
